Doer Biotech's National Postdoctoral Research Station Officially Launched Amid IPO Filing
Doer Biologics
Biological Drug Developer
Recently, Zhejiang Doer Biologics' National Postdoctoral Research Station was officially awarded and established. This recognition affirms Doer Biologics' innovative technology platform, research and development capabilities, and excellent talent pool, marking another significant breakthrough in the construction of Doer Biologics' scientific research platform.
A postdoctoral research workstation refers to an organization, approved to recruit and train postdoctoral researchers, established within enterprises, research and production-oriented institutions, and special regional entities. It serves as an effective carrier that combines industry, academia, and research to enhance independent innovation capabilities. Such workstations can fully leverage the role of high-level scientific research talents in major project development, technological cooperation, and exchanges, thereby improving technological innovation capabilities and overall competitiveness.
The establishment of the postdoctoral workstation is an important part of Doer Biologics' innovative research and development and talent cultivation. Meanwhile, Zhejiang Doer Biologics Co., Ltd. has signed a joint postdoctoral recruitment cooperation agreement with Zhejiang University, a top-tier university in China. Currently, three doctors have successfully joined the station.
In the future, the postdoctoral workstation of Doer Biologics will, under the guidance of the China National Postdoctoral Management Office and the Ministry of Human Resources and Social Security, collaborate with top universities and research institutions in China to recruit outstanding research scholars, further stimulating the innovative and creative vitality of scientific research talents.
Doer Biologics sincerely invites outstanding scholars to join the Doer Biologics Postdoctoral Workstation, to collaborate with Doer colleagues in exploring key innovative biopharmaceutical projects, and to jointly promote the further integration of industry, academia, and research.
Doer Biologics is one of the few research and development enterprises in China that owns independent intellectual property rights technology platforms and is dedicated to the development of innovative biopharmaceuticals. Based on its unique technology platform, the company has developed multiple innovative multi-specific protein drugs based on multi-domain structures. Currently, Doer Biologics has five globally innovative drug projects entering clinical research both in China and abroad. In the future, Doer Biologics will continue to focus on the research of multi-specific innovative biopharmaceuticals based on multi-domain structures, continuously developing innovative biopharmaceuticals with independent intellectual property rights to address unmet clinical needs.
We are looking for a group of researchers who are passionate about life sciences and drug development, hardworking, and eager to learn. If you share the same vision, we welcome you to join Doer Biologics. For inquiries, please contact: hr@doerbio.com.